Inventor · disambiguated record
Xiaolun Wang
Also filed as: WANG XIAOLUN
23 granted patents·15 pending applications·92 citations·filing 2003–2025
94Inventor score
Files withMIRATI THERAPEUTICS INC20PFIZER8TAKEDA PHARMACEUTICAL3TAKEDA PHARMACEUTICALS CO3CARDURION PHARMACEUTICALS LLC2
Top patents by PatentIndex Score
38 records- 0197US11702424B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2020·Granted Jul 18, 2023·4 cites·8 claims
- 0296US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0395US9879022B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2016·Granted Jan 30, 2018·19 cites·22 claims
- 0495US9458168B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2015·Granted Oct 4, 2016·17 cites·44 claims
- 0592US12421253B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·1 cites·29 claims
- 0692US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0791US10793579B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2019·Granted Oct 6, 2020·3 cites·8 claims
- 0891US10543212B2Substituted amines for treating cardiac diseasesCARDURION PHARMACEUTICALS LLC·Filed 2018·Granted Jan 28, 2020·10 cites·11 claims
- 0989US11999753B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jun 4, 2024·1 cites·5 claims
- 1086US10329302B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2018·Granted Jun 25, 2019·3 cites·2 claims
- 1186US9040522B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2014·Granted May 26, 2015·7 cites·10 claims
- 1285US12202836B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 1385US10308615B2Heterocyclic compounds as inhibitors of Vanin-1 enzymePFIZER·Filed 2016·Granted Jun 4, 2019·3 cites·8 claims
- 1482US9345713B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2015·Granted May 24, 2016·3 cites·10 claims
- 1579US9708296B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jul 18, 2017·2 cites·8 claims
- 1677US12304915B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted May 20, 2025·0 cites·81 claims
- 1777US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1875US2025270220A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1970US2025388606A1Azaquinazoline pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2068US12398154B2Azaquinazoline pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Aug 26, 2025·0 cites·49 claims
- 2167US11702418B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jul 18, 2023·0 cites·72 claims
- 2266US2025382290A1Salts of sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2364US2025368649A1Tetrahydropyridopyrimidine pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2464US2024025907A1QUINAZOLINE PAN-KRas INHIBITORSMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2563US2025376483A1Prodrugs of pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2662US9944626B26-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Apr 17, 2018·0 cites·7 claims
- 2760US10407409B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Sep 10, 2019·0 cites·2 claims
- 2859US2024368153A1Aminopyridine-based MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2959US2025059182A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3058US7534905B2Reagents for asymmetric allylation, aldol, and tandem aldol and allyation reactionsUNIV COLUMBIA·Filed 2003·Granted May 19, 2009·4 cites·23 claims
- 3157US2019292157A1Novel heterocyclic compounds as inhibitors of vanin-1 enzymePFIZER·Filed 2019·Application pending·0 cites
- 3255US11197858B2Substituted amines for treating cardiac diseasesCARDURION PHARMACEUTICALS LLC·Filed 2020·Granted Dec 14, 2021·0 cites·8 claims
- 3355US2023357277A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3454US2023101312A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3554US2023339976A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3653US2023279025A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3746US2010029657A1Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses ThereofWYETH CORP·Filed 2009·Application pending·0 cites
- 3833US9371321B2Azaindole derivativesTAKEDA PHARMACEUTICAL·Filed 2015·Granted Jun 21, 2016·0 cites·37 claims
Join the waitlist — get patent alerts
Get an alert when Xiaolun Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →